Revolution Medicines, Inc.RVMDNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

globenewswire.com

Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline will be featured at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026 in San Diego.

defenseworld.net

Algert Global LLC Boosts Position in Revolution Medicines, Inc. $RVMD

Algert Global LLC boosted its holdings in Revolution Medicines, Inc. (NASDAQ: RVMD) by 141.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 166,315 shares of the company's stock after purchasing an additional 97,332 shares during the quarter. Algert Global LLC owned

defenseworld.net

General Atlantic L.P. Acquires New Position in Revolution Medicines, Inc. $RVMD

General Atlantic L.P. acquired a new stake in Revolution Medicines, Inc. (NASDAQ: RVMD) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,474,428 shares of the company's stock, valued at approximately $115,556,000. Revolution Medicines comprises about 3.5% of General Atlantic L.P.'s investment portfolio,

seekingalpha.com

Harbor Health Care ETF Q4 2025 Portfolio Review

Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly delivered strong absolute performance — driven by continued GLP-1 demand and the FDA approval of Zepbound — our underweight position in the name was a significant detractor from relative results. During the quarter, we purchased Avidity Biosciences, a clinical-stage biopharma company focused on RNA therapies for rare muscle diseases, and Abivax SA, a clinical-stage biopharma company focused on chronic inflammatory diseases.

defenseworld.net

Fisher Asset Management LLC Buys Shares of 7,305 Revolution Medicines, Inc. $RVMD

Fisher Asset Management LLC purchased a new stake in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 7,305 shares of the company's stock, valued at approximately $341,000. A number of other hedge funds have

seekingalpha.com

Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript

zacks.com

RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View

Revolution Medicines posts a wider-than-expected Q4 loss and sees 2026 operating expenses of $1.6B-$1.7B as it advances late-stage RAS pipeline studies.

seekingalpha.com

Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript

globenewswire.com

Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2025, and provided an update on corporate progress.

globenewswire.com

Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in a fireside chat as part of the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 at 9:50 a.m. ET.

defenseworld.net

20,000 Shares in Revolution Medicines, Inc. $RVMD Purchased by Raiffeisen Bank International AG

Raiffeisen Bank International AG acquired a new position in Revolution Medicines, Inc. (NASDAQ: RVMD) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 20,000 shares of the company's stock, valued at approximately $921,000. A number of other institutional investors and

globenewswire.com

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, February 25, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.

defenseworld.net

Revolution Medicines Conference: CEO Details Daraxonrasib Phase III Timeline, First-Line PDAC Push

Revolution Medicines (NASDAQ: RVMD) CEO Mark Goldsmith outlined the company's late-stage plans for its RAS(ON) inhibitor daraxonrasib, discussed expansion into first-line pancreatic cancer, and offered updates on colorectal cancer and earlier-stage pipeline efforts during a conversation with Guggenheim Senior Biotech Analyst Michael Schmidt. Phase III RASolute 302: OS event-driven readout expected in 1H 2026 Goldsmith said

seekingalpha.com

Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

defenseworld.net

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of “Buy” from Brokerages

Shares of Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) have been given an average recommendation of "Buy" by the eighteen brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and four have given a strong buy recommendation

globenewswire.com

Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.

seekingalpha.com

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market opportunity remains robust.

zacks.com

RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer

Revolution Medicines stock tanks after a WSJ report said Merck has withdrawn from buyout talks over price.

fool.com

Why Revolution Medicines Stock Plummeted by Almost 17% Today

An apparent suitor has withdrawn from talks about acquiring the biotech, according to a media report. That's particularly discouraging, given that this business was apparently discussing a deal in the tens of billions of dollars for Revolution.

youtube.com

Overlooked Stock: RVMD Sells After MRK Turns Away

Revolution Medicines (RVMD) reversed a lot of its recent rally on Monday after the Wall Street Journal reported that Merck (MRK) is no longer looking to buy the biotech firm. However, as George Tsilis explains, there may be more pressure pinning the stock beyond its potential missed acquisition story.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance